Vincent Rajkumar
@VincentRK
Editor-in-Chief, Blood Cancer Journal; Chairman @IMFmyeloma Board; Cancer & Myeloma Research; Opinions solely personal views https://bit.ly/3f4TnJl
I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives. 1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.
The Episode is out and available on YouTube. Thanks @VincentRK for your time and sharing valuable insights. We discuss ✅your inspiring and powerful journey from Madras to Minnesota ✅value of mentorship in shaping our future ✅your valuable and game changing work in the…
🎙️Empowering Oncologists: The 3Ms of @JasmineKambojMD's life - Madras, Minnesota, Myeloma! From his roots in India to becoming a global leader at @MayoClinic, Dr. @VincentRK shares his inspiring journey, game-changing work in multiple myeloma, and the power of mentorship,…
AQUILA trial showed that early intervention with daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Improved overall survival -Preserved quality of life nejm.org/doi/full/10.10… @nejm @thanosdimop @PlasmaCellPete @SagarLonialMD…
📣 𝕏 Post of the Day (July 23, 2025) Dr. Vincent Rajkumar, MD (@VincentRK) shares a key update on AQUILA: The European Commission (EC) has approved a new indication for DARZALEX ® (daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment of adult patients…
It’s just a huge deal to offer an option to treat this disease so much earlier
A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…
A one stop shop for the current risk stratification schema in plasma cell disorders! As always, thank you for being so generous with your time @VincentRK! Absolutely wonderful experience learning the art of scientific communication from the very best! #mmsm #bookmark
Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. @ZanwarSaurabh @myelomaMD @LeukemiaJnl Link: nature.com/articles/s4137…
A big first for SMM! EU clears J&J's Darzalex as first therapy for smoldering multiple myeloma. Congrats to the entire #myeloma community who fought hard for this to happen #mmsm. firstwordpharma.com/story/5983164
🎙️Empowering Oncologists: The 3Ms of @JasmineKambojMD's life - Madras, Minnesota, Myeloma! From his roots in India to becoming a global leader at @MayoClinic, Dr. @VincentRK shares his inspiring journey, game-changing work in multiple myeloma, and the power of mentorship,…
The European Commission was able to make the below drug regulatory decision before the FDA does & cancer drug Darzalex (Johnson & Johnson) is now the 1st ever approved treatment for high risk smoldering multiple myeloma (SMM)—based on Phase 3 AQUILA trial. More below $JNJ #mmsm
A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…